- Home
- ONCO
ONCO
Onconetix Inc.
as 11-24-2025 10:50am EST
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CINCINNATI |
| Market Cap: | 4.3M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 28.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -89.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.10 - $179.35 | Next Earning Date: | 11-13-2025 |
| Revenue: | $1,223,751 | Revenue Growth: | -34.58% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Onconetix Inc. News
ONCO Breaking Stock News: Dive into ONCO Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 months ago
Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel
GlobeNewswire
5 months ago
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
TipRanks
6 months ago
Onconetix receives additional delisting notice from Nasdaq
GlobeNewswire
6 months ago
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
GlobeNewswire
7 months ago
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
GlobeNewswire
8 months ago
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
TipRanks
8 months ago
Onconetix claims validation of prostate cancer test Proclarix in Danish cohort
GlobeNewswire
8 months ago
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
Compare ONCO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ONCO Onconetix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.